TABLE 2

Cancer Incidence Rates and APC of Rates in Children and Adolescents (Ages 0–19 Years) by Race or Ethnicity, United States, 2001–2009

ICCC GroupWhiteAfrican AmericanNon-HispanicHispanic
CountRateaAPCb (95% CI)CountRateaAPCb (95% CI)CountRateaAPCb (95% CI)CountRateaAPCb (95% CI)
All ICCC groups combined97 765177.910.0 (−0.5 to 0.5)13 779127.291.3 (0.2 to 2.5)c95 716171.660.3 (−0.2 to 0.7)24 421168.940.6 (0.0 to 1.3)
I Leukemias, myeloproliferative, myelodysplastic diseases26 28347.940.3 (−0.6 to 1.2)302227.971.2 (−0.3 to 2.7)23 39142.490.0 (−0.7 to 0.8)843356.621.3 (0.1 to 2.6)c
 I(a) Lymphoid leukemias19 25235.160.4 (−0.5 to 1.3)182016.891.9 (0.0 to 3.9)16 50830.150.1 (−0.8 to 1.1)632642.251.6 (0.1 to 3.1)c
 I(b) Acute myeloid leukemias43317.87−0.4 (−1.6 to 0.8)7707.10−0.4 (−5.2 to 4.7)42707.67−0.5 (−2.0 to 1.1)12728.720.2 (−1.7 to 2.1)
 I(c) Chronic myeloproliferative diseases11972.171.6 (−1.8 to 5.1)2121.951.5 (−3.8 to 7.1)11892.101.4 (−0.3 to 3.0)3602.511.9 (−4.7 to 9.0)
 I(d) Myelodysplastic syndrome, other myeloproliferative8261.50−0.6 (−5.2 to 4.2)1251.158211.480.3 (−3.0 to 3.7)2281.49−2.0 (−6.5 to 2.8)
 I(e) Unspecified and other specified leukemias6771.230.8 (−3.2 to 4.9)950.886031.09−1.4 (−5.5 to 2.9)2471.653.0 (−2.5 to 8.8)
II Lymphomas and reticuloendothelial neoplasms14 01525.530.1 (−0.6 to 0.8)230621.302.0 (−0.5 to 4.5)14 42525.450.9 (0.6 to 1.7)c302022.23−0.9 (−1.9 to 0.2)
 II(a) Hodgkin’s lymphomas725613.170.1 (−0.7 to 1.0)10679.842.9 (0.2 to 5.7)c736012.830.7 (−0.1 to 1.5)142010.83−0.2 (−2.5 to 2.1)
 II(b) Non-Hodgkin’s lymphomas (except Burkitt lymphoma)46108.420.2 (−0.7 to 1.0)9749.000.6 (−2.9 to 4.2)49588.810.9 (−0.4 to 2.2)10897.99−0.2 (−3.0 to 2.6)
 II(c) Burkitt lymphoma14372.65−1.0 (−4.4 to 2.6)1691.5714602.641.2 (−1.4 to 3.7)2521.77−5.6 (−13.1 to 2.6)
 II(d) Miscellaneous lymphoreticular neoplasms5320.962.1 (−3.7 to 8.1)540.494610.843.6 (−0.7 to 8.1)2021.22
 II(e) Unspecified lymphomas1800.33420.391860.33570.41
III CNS and miscellaneous intracranial and intraspinal neoplasms17 32231.76−0.5 (−1.6 to 0.7)245822.861.2 (−1.0 to 3.4)17 41631.630.3 (−0.7 to 1.2)371925.22−1.0 (−2.6 to 0.6)
 III(a) Ependymomas and choroid plexus tumor14712.68−1.8 (−4.8 to 1.3)2131.97−1.6 (−9.6 to 7.1)13932.53−1.2 (−4.3 to 2.0)4072.68−2.3 (−6.5 to 2.2)
 III(b) Astrocytomas871615.99−0.6 (−1.8 to 0.7)116310.812.3 (−1.5 to 6.4)886016.060.2 (−1.1 to 1.4)167311.53−0.5 (−2.9 to 1.9)
 III(c) Intracranial and intraspinal embryonal tumors36366.66−0.8 (−2.5 to 1.0)4464.14−0.6 (−3.0 to 1.9)34896.38−0.1 (−1.7 to 1.5)8755.76−2.1 (−5.2 to 1.1)
 III(d) Other gliomas29405.410.6 (−1.4 to 2.6)4624.321.7 (−2.1 to 5.6)30255.491.5 (0.1 to 2.9)c6284.32−1.4 (−6.5 to 4.0)
 III(e) Other specified intracranial/intraspinal neoplasms3160.58−2.4 (−7.0 to 2.5)1201.123890.70−1.8 (−6.1 to 2.8)730.50
 III(f) Unspecified intracranial and intraspinal neoplasms2430.445.9 (0.2 to 12.0)c540.502600.473.7 (−2.2 to 10.0)630.43
IV Neuroblastoma, other peripheral nervous cell tumors47398.50−1.5 (−3.4 to 0.5)7566.930.7 (−3.4 to 5.0)49509.08−0.6 (−2.4 to 1.4)9205.40−2.3 (−5.9 to 1.4)
 IV(a) Neuroblastoma and ganglioneuroblastoma46278.30−1.6 (−3.5 to 0.3)7346.730.7 (−3.3 to 4.9)48338.88−0.6 (−2.4 to 1.3)8935.21−2.9 (−6.5 to 0.9)
 IV(b) Other peripheral nervous cell tumors1120.20220.201170.21270.19
V Retinoblastoma15872.83−0.2 (−2.5 to 2.2)3793.43−0.3 (−2.9 to 2.3)15692.88−0.1 (−1.2 to 1.1)6003.43−0.7 (−5.1 to 3.9)
VI Renal tumors35376.41−0.4 (−1.2 to 0.4)8557.922.5 (1.6 to 3.5)c38727.110.8 (−0.4 to 2.0)8255.050.5 (−3.0 to 4.0)
 VI(a) Nephroblastoma, other nonepithelial renal tumors32525.89−0.7 (−1.5 to 0.0)7266.732.3 (0.6 to 3.6)c34856.420.3 (−0.8 to 1.5)7634.58−1.0 (−3.6 to 3.6)
 VI(b) Renal carcinomas2670.493.8 (−2.2 to 10.2)1251.153670.655.8 (3.3 to 8.4)c590.45
 VI(c) Unspecified malignant renal tumors180.03200.04
VII Hepatic tumors11622.091.5 (−2.5 to 5.6)1561.4311142.021.3 (−1.2 to 3.9)3632.253.5 (−5.6 to 13.4)
 VII(a) Hepatoblastoma8421.511.2 (−3.0 to 5.5)1000.917761.421.3 (−1.9 to 4.5)2741.593.1 (−6.5 to 13.7)
 VII(b) Hepatic carcinomas3080.562.6 (−2.4 to 8.0)550.513240.571.3 (−2.6 to 5.2)870.65
 VII(c) Unspecified malignant hepatic tumors
VIII Malignant bone tumors50859.32−0.7 (−1.8 to 0.3)7817.22−0.8 (−4.9 to 3.5)50308.91−0.9 (−1.7 to 0.0)c12559.490.5 (−1.7 to 2.7)
 VIII(a) Osteosarcomas26704.89−0.4 (−1.8 to 1.1)6225.75−0.7 (−5.6 to 4.4)27764.91−0.8 (−2.2 to 0.6)7705.870.8 (−1.7 to 3.3)
 VIII(b) Chondrosarcomas2060.37250.232100.37380.29
 VIII(c) Ewing tumor and related sarcomas of bone18743.44−1.1 (−3.1 to 0.9)700.6517053.03−1.2 (−3.8 to 1.5)3492.600.7 (−3.2 to 4.7)
 VIII(d) Other specified malignant bone tumors2330.43−2.8 (−8.8 to 3.7)400.372400.42−0.2 (−5.7 to 5.8)600.45
 VIII(e) Unspecified malignant bone tumors1020.19240.22990.18380.28
IX Soft tissue and other extraosseous sarcomas654311.93−0.1 (−0.8 to 0.7)135912.551.4 (−0.4 to 3.1)679112.150.5 (−0.4 to 1.5)162811.49−0.2 (−2.2 to 1.8)
 IX(a) Rhabdomyosarcomas25994.75−1.7 (−3.7 to 0.3)5264.882.8 (−1.7 to 7.6)26454.79−0.8 (−3.5 to 1.9)6544.420.2 (−4.7 to 5.4)
 IX(b) Fibrosarcomas, peripheral nerve, other fibrous7361.340.1 (−3.0 to 3.3)1591.467421.321.0 (−2.6 to 4.7)1981.40−6.7 (−10.9 to −2.3)c
 IX(c) Kaposi sarcoma220.04
 IX(d) Other specified soft tissue sarcomas25534.650.8 (−1.4 to 3.0)5204.791.1 (−2.2 to 4.6)26884.761.1 (−0.9 to 3.0)6164.530.6 (−2.3 to 3.7)
 IX(e) Unspecified soft tissue sarcomas6441.173.2 (−0.5 to 7.0)1421.316941.233.1 (−0.5 to 6.7)1561.11
X Germ cell, trophoblastic tumors, neoplasms of gonads654611.810.6 (−1.0 to 2.2)6626.071.4 (−0.2 to 3.1)591410.350.3 (−1.0 to 1.6)190014.261.6 (−0.6 to 3.8)
 X(a) Intracranial and intraspinal germ cell tumors9001.650.5 (−2.7 to 3.7)1000.928901.581.1 (−1.9 to 4.2)2431.81−0.3 (−4.8 to 4.4)
 X(b) Extracranial and extragonadal germ cell tumors7841.40−1.8 (−4.4 to 0.7)1521.388001.44−1.3 (−3.9 to 1.4)2461.66−4.5 (−7.8 to −1.2)c
 X(c) Malignant gonadal germ cell tumors44688.051.0 (−0.9 to 2.8)3493.213.5 (−0.3 to 8.0)38386.660.4 (−1.3 to 2.2)13049.962.5 (−0.7 to 5.8)
 X(d) Gonadal carcinomas2350.424.0 (−1.8 to 10.1)180.172160.373.6 (−1.8 to 9.2)650.51
 X(e) Other and unspecified malignant gonadal tumors1590.29430.391700.30420.32
XI Other malignant epithelial neoplasms and melanomas10 51119.020.7 (−0.3 to 1.7)9608.831.4 (−2.8 to 5.9)10 78918.770.4 (−0.5 to 1.3)163912.674.9 (2.7 to 7.1)c
 XI(a) Adrenocortical carcinomas1300.241210.22300.20
 XI(b) Thyroid carcinomas41827.574.9 (2.9 to 6.9)c2552.356.6 (0.7 to 12.8)c39746.894.1 (2.3 to 5.9)c8386.539.1 (5.4 to 12.8)c
 XI(c) Nasopharyngeal carcinomas1940.352.0 (−1.5 to 5.6)1801.653510.61−0.8 (−6.4 to 5.1)610.48
 XI(d) Malignant melanomas36946.68−3.9 (−6.8 to −0.9)c540.5038296.66−3.5 (−6.3 to −0.6)c2181.64−2.0 (−5.7 to 1.0)
 XI(e) Skin carcinomas440.08510.09
 XI(f) Other and unspecified carcinomas22674.111.0 (−0.6 to 2.6)4554.18−0.5 (−4.3 to 3.5)24634.291.2 (0.0 to 2.4)c4853.781.1 (−1.9 to 4.1)
XII Other and unspecified malignant neoplasms4350.79−1.0 (−3.7 to 1.8)850.784550.810.4 (−4.3 to 5.2)1190.83
  • a Rates are per million and were age-adjusted to the 2000 US standard population (19 age groups, Census P25-1130) standard. Rate statistics were not displayed if case count was <16 cases.

  • b APCs were calculated by using weighted least squares method. Statistical significance was determined if the 95% CI of APC did not include zero (P < .05). APC was not calculated if case count was <16 cases in any 1 year. Some significant values appear to include zero because APC was rounded to the nearest 10th.

  • c Denotes significant APC.